BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-12.68%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.45B
AUM Growth
+$2.45B
(-17%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
4.62%
Top 10 Holdings %
Top 10 Hldgs %
73.47%
Holding
55
New
2
Increased
12
Reduced
5
Closed
4
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$57.7M |
| 2 |
Axsome Therapeutics
AXSM
|
$35.2M |
| 3 |
Kura Oncology
KURA
|
$34.2M |
| 4 |
Protagonist Therapeutics
PTGX
|
$32.6M |
| 5 |
Revolution Medicines
RVMD
|
$28.3M |
Top Sells
| 1 |
Agios Pharmaceuticals
AGIO
|
$35.3M |
| 2 |
89bio
ETNB
|
$33.9M |
| 3 |
GH Research
GHRS
|
$17.3M |
| 4 |
enGene Holdings
ENGN
|
$14M |
| 5 |
Xoma
XOMA
|
$13M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $772M | 31.45% | 19,751,284 | – | – |
|
|
2
Axsome Therapeutics
AXSM
$6.05B
| $197M | 8.03% | 1,690,221 +302,157 | +22% | +$35.2M |
|
|
3
Revolution Medicines
RVMD
$7.1B
| $176M | 7.18% | 4,982,384 +801,205 | +19% | +$28.3M |
|
4
Kymera Therapeutics
KYMR
$2.95B
| $141M | 5.76% | 5,161,801 | – | – |
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $126M | 5.13% | 2,796,513 | – | – |
|
|
6
Protagonist Therapeutics
PTGX
$3.67B
| $125M | 5.08% | 2,575,015 +675,000 | +36% | +$32.6M |
|
|
7
GH Research
GHRS
$837M
| $97.4M | 3.97% | 8,827,712 -1,572,446 | -15% | -$17.3M |
|
|
8
Xoma
XOMA
$392M
| $59.5M | 2.42% | 2,983,026 -650,717 | -18% | -$13M |
|
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $57.7M | 2.35% | +1,913,385 | New | +$57.7M |
|
10
Zymeworks
ZYME
$1.12B
| $51.3M | 2.09% | 4,308,935 | – | – |
|
|
11
Kura Oncology
KURA
$686M
| $51.2M | 2.09% | 7,754,129 +5,186,660 | +202% | +$34.2M |
|
12
Cullinan Oncology
CGEM
$445M
| $43.5M | 1.77% | 5,750,683 | – | – |
|
13
AC Immune
ACIU
$205M
| $37.1M | 1.51% | 19,822,436 +300,000 | +2% | +$561K |
|
14
Tyra Biosciences
TYRA
$675M
| $36.7M | 1.5% | 3,944,194 | – | – |
|
15
Galapagos
GLPG
$2.07B
| $36.5M | 1.49% | 1,454,422 -115,000 | -7% | -$2.89M |
|
16
Celcuity
CELC
$2.17B
| $35M | 1.43% | 3,466,000 | – | – |
|
|
VERV
17
DELISTED
Verve Therapeutics
VERV
| $31.6M | 1.29% | 6,904,050 | – | – |
|
18
Structure Therapeutics
GPCR
$1.11B
| $30.7M | 1.25% | 1,771,417 | – | – |
|
19
Xencor
XNCR
$580M
| $29.2M | 1.19% | 2,740,141 +451,381 | +20% | +$4.8M |
|
20
Monte Rosa Therapeutics
GLUE
$296M
| $26.3M | 1.07% | 5,660,132 +2,895,661 | +105% | +$13.4M |
|
|
SEPN
21
Septerna, Inc. Common Stock
SEPN
$539M
| $25.5M | 1.04% | 4,396,124 +1,944,100 | +79% | +$11.3M |
|
22
Eledon Pharmaceuticals
ELDN
$155M
| $21.3M | 0.87% | 6,293,282 | – | – |
|
23
Cidara Therapeutics
CDTX
$1.66B
| $19.9M | 0.81% | 924,642 -168,154 | -15% | -$3.62M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $19.9M | 0.81% | 5,295,893 -420,000 | -7% | -$1.58M |
|
|
PVLA
25
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $19.5M | 0.79% | 696,555 | – | – |
|